Urology Textbook
Clinical Essentials
By Dirk Manski, MD

 You are here: Urology Textbook > Drugs in Urology > Anticholinergics > Fesoterodine

Fesoterodine: Mechanism of Action, Adverse Effects, Contraindications, and Dosage

Mechanism of Action

Fesoterodine is a lipophilic tertiary amine with anticholinergic effects on muscarinic receptors. After oral absorption, fesoterodine is hydrolyzed into an active metabolite (5-hydroxymethyl tolterodine, as with tolterodine). In direct comparison with tolterodine, fesoterodine has advantages in terms of efficacy and tolerability.

The inhibition of M3 receptors with Fesoterodine reduces smooth muscle detrusor contraction, increases functional bladder capacity, and alleviates symptoms of urgency. Fesoterodine is used to treat overactive bladder, urge incontinence, neurogenic lower urinary tract dysfunction and catheter-related bladder discomfort (CRBD).

Pharmacokinetics of Fesoterodine:

After oral adsorption, there is a reliable metabolism to 5-hydroxymethyl tolterodine. Mainly renal excretion of the metabolites, with a half-life of seven hours.

Adverse Effects of Fesoterodine

Muscarinic receptors are present in numerous organs. M3 receptors are mainly found in smooth muscle and glands. Fesoterodine exhibits some organ selectivity and may result in fewer side effects compared to other anticholinergics.

Eye:
Gastrointestinal tract:
Heart:
CNS:
Skin:

Drug Interactions

Increased anticholinergic effect with antiparkinson drugs, antihistamines, antipsychotics, and tricyclic antidepressants. Amplification of the tachycardic effect of sympathomimetic medications. Fesoterodine mitigates the effects of gastrointestinal prokinetics. Ketakonazole and macrolid antibiotics may increase the plasma concentration of Fesoterodine.

Contraindications of Fesoterodine

Dosage of Fesoterodine:

The starting dose is 4 mg once daily. Depending on effectiveness, the dose may be increased to 8 mg once daily. Full effect is achieved after 2–8 weeks of therapy. Do not increase the dosage in patients with severe hepatic or renal insufficiency or concomitant administration of inhibitors of cytochrome CYP3A4 such as ketoconazole or macrolide antibiotics.






Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

References

Ouslander 2004 OUSLANDER, J. G.: Management of overactive bladder.
In: N Engl J Med
350 (2004), Nr. 8, S. 786–99

Yoshimura und Chancellor 2002 YOSHIMURA, N. ; CHANCELLOR, M. B.: Current and future pharmacological treatment for overactive bladder.
In: J Urol
168 (2002), Nr. 5, S. 1897–913



  Deutsche Version: Nebenwirkungen und Dosierung von Fesoterodin

Urology-Textbook.com – Choose the Ad-Free, Professional Resource

This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.

New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.

-->